Entasis reports Phase I data for anti-infective ETX2514

Entasis Therapeutics Inc. (Waltham, Mass.) reported data from a double-blind, placebo-controlled, Australian Phase I trial in 124 healthy volunteers showing that single and multiple ascending doses of IV ETX2514 given alone or in combination with sulbactam and/or imipenem/cilastatin were generally well tolerated. The most common adverse events reported were headaches, catheter-site inflammation, mild drowsiness and nausea. Data were presented at the IDWeek meeting in San Diego.

In Phase II, Entasis plans to evaluate ETX2514 in combination with sulbactam to treat Acinetobacter baumannii infections and in combination with imipenem to treat undisclosed Gram-negative infections...